Plerixafor in non-Hodgkin’s lymphoma and multiple myeloma patients undergoing autologous stem cell transplantation
Autologous stem cell transplantation (ASCT) is the standard of care for multiple myeloma (MM) and relapsing non-Hodgkin’s lymphoma (NHL) patients. Peripheral blood stem cells (PBSC) have become the main source of grafts for ASCT due to several advantages over bone marrow grafts. Poor PBSC mobilizati...
Main Author: | Jan S. Moreb |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2011-10-01
|
Series: | Oncology Reviews |
Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/2 |
Similar Items
-
Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients
by: Jan S. Moreb, et al.
Published: (2011-01-01) -
Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin’s lymphoma and multiple myeloma
by: Louis M Pelus, et al.
Published: (2011-02-01) -
Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma
by: Rishi Agarwal, et al.
Published: (2012-12-01) -
The illustration of the successful mobilization of hematopoietic stem cells using plerixafor and pegfilgrastim in the patient with non-hodgkin's lymphoma
by: M S Motalkina, et al.
Published: (2015-06-01) -
Case Study in RefractoryNon-Hodgkin’s Lymphoma: Successful Treatment with Plerixafor
by: Hamdy Abdel Azim, et al.
Published: (2011-09-01)